Moderna CEO sees another round of COVID booster jabs in the fall | Coronavirus pandemic news

Stephane Bancel, CEO of Moderna Inc, also said that Omicron may quickly enter the pandemic phase, and most people will be exposed to the coronavirus.

go through Bloomberg

Moderna Inc. CEO Stephane Bancel said that another round of vaccine boosters against Covid-19 may be needed this fall, even if immunity to the rapidly spreading variant of omicron becomes widespread.

The vaccine chief executive stated in a speech at a healthcare conference hosted by Goldman Sachs Group Inc. on Thursday night that the highly contagious omicron could quickly make the world enter the epidemic phase, and most people are exposed to it. Through the virus. But it is not clear how long it will take. He said that the current round of enhancers’ protective effects will be effective before they subside, and scientists cannot predict the potential impact of future mutations on the severity of the disease.

“Assuming that omicron accelerates the popular phase, I still believe that we will need boosters in the fall of 22 and beyond,” Bansell said in a speech. However, he said that the boost for this month or the last quarter of 2021 may continue until the beginning of the northern hemisphere spring.

Stephane Bancel, CEO of Moderna Inc.Stephane Bancel, CEO of Moderna [File: Bloomberg]

Moderna and competitors Pfizer and BioNTech SE are interested in pushing policy makers to conduct routine Covid injections. Countries around the world have launched boosters in an attempt to slow down the spread of omicron, although it is not clear how long the boosters can prevent infection. Israel has begun to provide a fourth dose of the vaccine to people 60 years and older, as the country is struggling to cope with a record number of new cases.

Early data from the United Kingdom showed last month that the enhancer protection against omicron infection weakened faster than against delta variants. However, if the pattern previously seen in delta holds true, vaccines will continue to prevent people from getting serious illnesses.

Bansell said that Moderna is continuing to study omicron-specific lenses and expects to begin human trials soon. He said that the company will continue to study shots for different combinations of strains.

At 9:39 am New York time, the stock rose 1.2%.

(Update the sharing in the last paragraph.)